Clinical trial
SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions
NCT01171820 is registered in ClinicalTrials.gov with Abbott Medical Devices as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions
- Lead sponsor
- Abbott Medical Devices
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- November 30, 2006
- Completion date
- July 31, 2010
- Enrollment
- 324 (actual)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.